eXagen™ is currently developing two breast cancer prognostic assays, eXagenBC™ for estrogen receptor/progesterone receptor positive (ER/PR+) patients and another test for ER/PR- patients. Both tests use fluorescent in situ hybridization (FISH) technology to assess the likelihood of breast cancer recurrence in women with newly diagnosed, early stage invasive ductal breast cancer. eXagenBC has been submitted for 510(k) clearance.